Pacific Udall Center researcher and collaborator publications include:

  1. Aasly JO, Shi M, Sossi V, Stewart T, Johansen KK, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Kim HM, Leverenz JB, Ginghina C, Armaly J, Edwards KL, Snapinn KW, Stoessl AJ, Zhang J. Cerebrospinal fluid amyloid beta and tau in LRRK2 mutation carriers. Neurology 2012; 78:55-61. PMC3466497
  2. Askren MK, McAllister-Day TK, Koh N, Mestre Z, Dines JN, Korman BA, Melhorn SJ, Peterson DJ, Peverill M, Qin X, Rane SD, Reilly MA, Reiter MA, Sambrook KA, Woelfer KA, Grabowski TJ, Madhyastha TM. Using Make for Reproducible and Parallel Neuroimaging Workflow and Quality-Assurance. Front Neuroinform 2016; 10:2. PMC4735413
    1. Beecham GW, Dickson DW, Scott WK, Martin ER, Schellenberg G, Alzheimer Disease Genetics Consortium, Nuytemans K, Larson EB, Buxbaum JD, Trojanowski JQ, Van Deerlin VM, Hurtig HI, Mash DC, Beach T, Troncoso JC, Pletnikova O, Frosch MP, Ghetti B, Foroud TM, Honig LS, Marder K, Vonsattel JP, Goldman SM, Vinters HV, Ross OA, Wszolek ZK, Wang L, Dykxhoorn DM, Montine TJ, Leverenz JB, Dawson TM, Vance JM. Clarifying Genetic Heterogeneity in Neurodegeneration: GWAS of autopsy-defined Parkinson Disease cases and controls demonstrates that the PARK 10 locus is a major locus for neuropathologic Parkinson disease, in press.
  3. Bekris LM, Galloway NM, Millard S, Lockhart D, Li G, Galasko DR, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Leverenz JB, Seubert P, Tsuang DW, Peskind ER, Yu CE. Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer’s disease. Neurobiol Aging 2011; 32:556 e513-523. PMC3065534
    1. Bekris LM, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang DW, Montine TJ, Peskind ER, Yu CE. ADAM10 expression and promoter haplotype in Alzheimer’s disease. Neurobiol Aging 2012; 33:2229 e2221-2229. PMC3391324
  4. Bekris LM, Lutz F, Montine TJ, Yu CE, Tsuang D, Peskind ER, Leverenz JB. MicroRNA in Alzheimer’s disease: an exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers 2013; 18:455-66. PMC3967870
    1. Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 2010; 23:228-242. PMC3044594
  5. Bekris LM, Millard S, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang DW, Yu CE, Peskind ER. Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet, 2012;159B:874-83. PMC3826266.
  6. Bekris LM, Millard S, Tsuang DW, Peskind ER, Yu CE, Montine TJ, Zhang J, Zabetian CP, Leverenz JB. Cerebrospinal Fluid Aβ42 Levels and APP Processing Pathway Genes in Parkinson’s Disease. Mov Disord. 2015 Jun;30(7):936-44. PMC4478197.
  7. Bekris LM, Tsuang DW, Peskind ER, Yu CE, Montine TJ, Zhang J, Zabetian CP, Leverenz JB. Cerebrospinal fluid Abeta42 levels and APP processing pathway genes in Parkinson’s disease. Mov Disord 2015; 30:936-44.  PMC4478197
    • Beutler LR, Eldred KC, Quintana A, Keene CD, Rose SE, Postupna N, Montine TJ, Palmiter RD. Severely impaired learning and altered neuronal morphology in mice lacking NMDA receptors in medium spiny neurons. PLoS One 2011; 6:e28168. PMC3221701
  8. Boord P, Madhyastha TM, Askren MK, Grabowski TJ. Executive attention networks show altered relationship with default mode network in PD. Neuroimage Clin. 2016 Nov 5;13:1-8. PMC5121155.
  9. Burdick DJ, Cholerton B, Watson GS, Siderowf A, Trojanowski JQ, Weintraub D, Ritz B, Rhodes SL, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Srivatsal S, Edwards KL, Montine TJ, Zabetian CP, Leverenz JB. People with Parkinson’s disease and normal MMSE score have a broad range of cognitive performance. Mov Disord. 2014 Sep;29(10):1258-64. PMC4162839.
  10. Caudle WM, Bammler TK, Lin Y, Pan S, Zhang J. Using ‘omics’ to define pathogenesis and biomarkers of Parkinson’s disease. Expert Rev Neurother 2010; 10:925-942. PMC2913169
  11. Chahine LM, Qiang JK, Ashbridge E, Minger J, Yearout D, Horn S, Colcher A, Hurtig H, Lee VM, Van Deerlin VM, Leverenz JB, Siderowf A, Trojanowski JQ, Zabetian CP, Chen-Plotkin A. Clinical and biochemical differences in Parkinson’s patients with and without GBA mutations. JAMA Neurol 2013; 70:852-8. PMC3762458
  12. Chahine LM, Stern MB, Chen-Plotkin A. Blood-based biomarkers for Parkinson’s disease. Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S99-103. PMC4070332
  13. Cholerton B, Larson EB, Baker LD, Craft S, Crane PK, Millard SP, Sonnen JA, Montine TJ. Neuropathologic correlates of cognition in a population-based sample. J Alzheimers Dis 2013; 36:699-709. PMC3737376
  14. Cholerton B, Larson EB, Quinn JF, Zabetian CP, Mata IF, Keene CD, Flanagan M, Crane PK, Grabowski TJ, Montine KS, Montine TJ. Precision Medicine: Clarity for the Complexity of Dementia. Am J Pathol 2016; 186:500-6. PMC4816691
  15. Cholerton BA, Zabetian CP, Quinn JF, Chung KA, Peterson A, Espay AJ, Revilla FJ, Devoto J, Watson GS, Hu SC, Edwards KL, Montine TJ, Leverenz JB. Pacific Northwest Udall Center of Excellence Clinical Consortium: Study design and baseline cohort characteristics. J Parkinsons Dis. 2013; 3:205-14. PMC3779428
  16. Cholerton BA, Zabetian CP, Wan JY, Montine TJ, Quinn JF, Mata IF, Chung KA, Peterson A, Espay AJ, Revilla FJ, Devoto J, Watson GS, Hu SC, Leverenz JB, Edwards KL. Evaluation of mild cognitive impairment subtypes in Parkinson’s disease. Mov Disord. 2014; 29:756-64. PMC4013249.
  17. Christie D, Shofer J, Millard SP, Li E, Demichele-Sweet MA, Weamer EA, Kamboh MI, Lopez OL, Sweet RA, Tsuang D. Genetic association between APOE*4 and neuropsychiatric symptoms in patients with probable Alzheimer’s disease is dependent on the psychosis phenotype. Behav Brain Funct 2012; 8:62. PMC3549850
  18. Cohen RG, Klein KA, Nomura M, Fleming M, Mancini M, Giladi N, Nutt JG, Horak FB. Inhibition, executive function, and freezing of gait. J Parkinsons Dis. 2014 Jan 1;4(1):111-22. PMC4028962
  19. Cook TJ, Hoekstra JG, Eaton DL, Zhang J. Mortalin is Expressed by Astrocytes and Decreased in the Midbrain of Parkinson’s Disease Patients. Brain Pathol. 2016 Jan;26(1):75-81. PMC4676952.
  20. Cooper CA, Jain N, Gallagher MD, Weintraub D, Xie SX, Berlyand Y, Espay AJ, Quinn J, Edwards KL, Montine T, Van Deerlin VM, Trojanowski J, Zabetian CP, Chen-Plotkin AS. Common variant rs356182 near SNCA defines a Parkinson’s disease endophenotype. Ann Clin Transl Neurol. 2016 Nov 25;4(1):15-25. PMC5221454.
  21. Cornejo MR, Torres L, Mata I, Mazzetti PE, Rivas D, Cosentino C, Inca-Martinez M,Cuba JM, Zabetian CP, Leverenz JB. A Peruvian family with a novel PARK2 mutation: Clinical and Pathological Characteristics. Parkinsonism Relat Disord 2015; 21:444-8. PMC4527610
  22. Costa-Mallen P, Zabetian CP, Agarwal P, Hu SC, Yearout D, Samii A, Leverenz JB, Roberts JW, Checkoway H. Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease risk. Parkinsonism Relat Disord 2015; 21:1087-92. PMC4554997
  23. Costa-Mallen P, Zabetian CP, Hu SC, Agarwal P, Yearout D, Checkoway H. Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels in Parkinson disease. J Neural Transm (Vienna). 2016 Nov;123(11):1319-1330. PMC5096643.
  24. Costa-Mallen P, Zabetian CP, Agarwal P, Hu SC, Yearout D, Samii A, Leverenz JB, Roberts JW, Checkoway H. Response to the letter “Haptoglobin phenotype and Parkinson disease risk” by Delanghe et al. Parkinsonism Relat Disord. 2016 Jan;22:110-1. PMC5096650.
  25. Crane PK, Gibbons LE, Dams-O’Connor K, Trittschuh E, Leverenz JB, Keene CD, Sonnen J, Montine TJ, Bennett DA, Leurgans S, Schneider JA, Larson EB. Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings. JAMA Neurol. 2016 Sep 1;73(9):1062-9. PMC5319642.
  26. Darvas M, Fadok JP, Palmiter RD. Requirement of dopamine signaling in the amygdala and striatum for learning and maintenance of a conditioned avoidance response. Learn Mem 2011; 18:136-143. PMC3120097
  27. Darvas M, Henschen CW, Palmiter RD. Contributions of signaling by dopamine neurons in dorsal striatum to cognitive behaviors corresponding to those observed in Parkinson’s disease. Neurobiol Dis. 2014; 65:112-123. PMC4001780
  28. Darvas M, Palmiter RD. Contributions of striatal dopamine signaling to the modulation of cognitive flexibility. Biol Psychiatry 2011; 69:704-707. PMC3120097
  29. Darvas M, Palmiter RD. Restricting dopaminergic signaling to either dorsolateral or medial striatum facilitates cognition. J Neurosci 2010; 30:1158-65. PMC3771669
  30. Darvas M, Palmiter RD. Specific contributions of N-methyl-d-aspartate receptors in the dorsal striatum to cognitive flexibility. Neuroscience. 2015 Jan 22;284:934-42. PMC4267923.
  31. Darvas M, Wunsch AM, Gibbs JT, Palmiter RD. Dopamine dependency for acquisition and performance of Pavlovian conditioned response. Proc Natl Acad Sci USA. 2014; 111:2764-9. PMC3932907.
  32. Davis MY, Johnson CO, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Quinn JF, Chung KA, Peterson-Hiller AL, Rosenthal LS, Dawson TM, Albert MS, Goldman JG, Stebbins GT, Bernard B, Wszolek ZK, Ross OA, Dickson DW, Eidelberg D, Mattis PJ, Niethammer M, Yearout D, Hu SC, Cholerton BA, Smith M, Mata IF, Montine TJ, Edwards KL, Zabetian CP. Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurol. 2016 Oct 1;73(10):1217-1224. PMC5056861.
  33. Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, Goodlett DR, Wang Y, Armaly J, Tumas V, Zabetian CP, Leverenz JB, Shi M, Zhang J. Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson’s disease. Brain 2011; 134:e178. PMC3122368
  34. Dombroski BA, Galasko DR, Mata IF, Zabetian CP, Craig UK, Garruto RM, Oyanagi K, Schellenberg GD. C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis/parkinsonism dementia complex. JAMA Neurol 2013;15:1-4. PMC3771869
  35. Erten-Lyons D, Woltjer R, Kaye J, Mattek N, Dodge HH, Green S, Tran H, Howieson DB, Wild K, Silbert LC. Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology 2013; 81:977-83. PMC3888199
  36. Fadok JP, Darvas M, Dickerson TM, Palmiter RD. Long-term memory for pavlovian fear conditioning requires dopamine in the nucleus accumbens and basolateral amygdala. PLoS One 2010; 5:e12751. PMC2939886
  37. Flanagan M, Larson EB, Latimer CS, Cholerton B, Crane PK, Montine KS, White LR, Keene CD, Montine TJ. Clinical-pathologic correlations in vascular cognitive impairment and dementia. Biochim Biophys Acta 2016; 1862:945-51. PMC4769968
  38. Fling BW, Cohen RG, Mancini M, Carpenter SD, Fair DA, Nutt JG, and Horak FB. Functional reorganization of the locomotor network in Parkinson patients with freezing of gait. PLoS One. 2014 Jun 17;9(6):e100291. PMC4061081
  39. Fling BW, Cohen, RG, Mancini, M, Nutt, JG, Fair, DA, and Horak, FB. Asymmetric pedunculopontine network connectivity in parkinsonian patients with freezing of gait. Brain. 2013; 136:2405-18. PMC3722352
  40. Fling BW, Nutt JG, Horak FB. Reply: Does dominant pedunculopontine nucleus exist? Probably not. Brain. 2014 Nov 2. pii: awu317. PMC exempt per NIHMS
  41. Furlong CE, Suzuki SM, Stevens RC, Marsillach J, Richter RJ, Jarvik GP, Checkoway H, Samii A, Costa LG, Griffith A, Roberts JW, Yearout D, Zabetian CP. Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact 2010; 187:355-361. PMC3035622
  42. Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P, Alzheimer’s Disease Cooperative Study Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 2012; 69 836-41. PMC3661272
  43. Gallardo CM, Darvas M, Oviatt M, Chang CH, Michalik M, Huddy TF, Meyer EE, Shuster SA, Aguayo A, Hill EM, Kiani K, Ikpeazu J, Martinez JS, Purpura M, Smit AN, Patton DF, Mistlberger RE, Palmiter RD, Steele AD. Dopamine receptor 1 neurons in the dorsal striatum regulate food anticipatory circadian activity rhythms in mice. Elife. 2014 Sep 12;3:e03781. PMC4196120.
  44. Gonzalez-Cuyar LF, Sonnen JA, Montine KS, Keene CD, Montine TJ. Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment. Curr Neurol Neurosci Rep 2011; 11:455-463. PMC3213691
  45. Guthrie CR, Greenup L, Leverenz JB, Kraemer BC. MSUT2 is a determinant of susceptibility to tau neurotoxicity. Hum Mol Genet 2011; 20:1989-1999. PMC3080609
  46. Hall TO, Wan JY, Mata IF, Kerr KF, Snapinn KW, Samii A, Roberts JW, Agarwal P, Zabetian CP, Edwards KL Risk prediction for complex diseases: application to Parkinson’s disease. Genet Med 2013;15:361-367. PMC3687522.
  47. Halliday GM, Leverenz JB, Schneider JS, Adler CH. The neurobiological basis of cognitive impairment in Parkinson’s disease. Mov Disord. 2014; 29:634-50. PMC4049032
  48. Hatano T, Funayama M, Kubo S, Mata IF, Oji Y, Mori A, Zabetian CP, Waldherr SM, Yoshino H, Oyama G, Shimo Y, Fujimoto K, Oshima H, Kunii Y, Yabe H, Mizuno Y, Hattori N. Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson’s disease. Neurobiol Aging. 2014 Nov;35(11):2656.e17-23. PMC4171438.
  49. Henschen CW, Palmiter RD, Darvas M. Restoration of dopamine signaling to the dorsal striatum is sufficient for aspects of active maternal behavior in female mice. Endocrinology 2013; 154:4316-27. PMC journal in process.
  50. Ho L, Zhao W, Dams-O’Connor K, Tang CY, Gordon W, Peskind ER, Yemul S, Haroutunian V, Pasinetti GM. Elevated plasma MCP-1 concentration following traumatic brain injury as a potential ”predisposition” factor associated with an increased risk for subsequent development of Alzheimer’s disease. J Alzheimers Dis 2012; 31:301-13. PMC3576700
  51. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 2010; 133:713-726. PMC2842513
  52. Hossein-Nezhad A, Fatemi RP, Ahmad R, Peskind ER, Zabetian CP, Hu SC, Shi M, Wahlestedt C, Zhang J, Faghihi MA. Transcriptomic Profiling of Extracellular RNAs Present in Cerebrospinal Fluid Identifies Differentially Expressed Transcripts in Parkinson’s Disease. J Parkinsons Dis. 2016;6(1):109-17. PMC4927907.
  53. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 2012; 8:1-13. PMC3266529
  54. Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, Lee EB, Van Deerlin VM, Lopez OL, Kofler JK, Nelson PT, Jicha GA, Woltjer R, Quinn JF, Kaye J, Leverenz JB, Tsuang D, Longfellow K, Yearout D, Kukull W, Keene CD, Montine TJ, Zabetian CP, Trojanowski JQ. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol. 2017 Jan;16(1):55-65. PMC5181646.
  55. Irwin DJ, White M, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VMY, Leverenz JB, Montine TJ, Duda J, Hurtig HI, and Trojanowski JQ. Neuropathologic substrates of Parkinson’s disease dementia. Ann Neurol 2012; 72:587-98. PMC3484250
  56. Jayadev S, Nochlin D, Poorkaj P, Steinbart EJ, Mastrianni JA, Montine TJ, Ghetti B, Schellenberg GD, Bird TD, Leverenz JB. Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype. Ann Neurol 2011; 69:712-720. PMC3114566
  57. Karlawish J, Cary M, Moelter ST, Siderowf A, Sullo E, Xie S, Weintraub D. Cognitive impairment and PD patients’ capacity to consent to research. Neurology 2013; 81:801-7. PMC3908465.
  58. Kay DM, Stevens CF, Hamza TH, Montimurro JS, Zabetian CP, Factor SA, Samii A, Griffith A, Roberts JW, Molho ES, Higgins DS, Gancher S, Moses L, Zareparsi S, Poorkaj P, Bird T, Nutt J, Schellenberg GD, Payami H. A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. Neurology 2010; 75:1189-1194. PMC3013490
  59. Kelly VE, Johnson CO, McGough EL, Shumway-Cook A, Horak FB, Chung KA, Espay AJ, Revilla FJ, Devoto J, Wood-Siverio C, Factor SA, Cholerton B, Edwards KL, Peterson AL, Quinn JF, Montine TJ, Zabetian CP, Leverenz JB. Association of cognitive domains with postural instability/gait disturbance in Parkinson’s disease. Parkinsonism Relat Disord 2015; 21:692-7. PMC4524498
  60. Korff A, Liu C, Ginghina C, Shi M, Zhang J. α-Synuclein in Cerebrospinal Fluid of Alzheimer’s Disease and Mild Cognitive Impairment. J Alzheimer’s Dis. 2013; 36:679-88. PMC3740054.
  61. Korvatska O, Strand NS, Berndt JD, Strovas T, Chen D-H, Leverenz JB, Kiianitsa K, Mata IF, Karakoc E, Greenup JL, Bonkowski E, Chuang J, Moon RT, Eichler EE, Nickerson DA, Zabetian CP, Kraemer BC, Bird TD, Raskind WH. Altered splicing of ATP6AP2 causes X-linked parkinsonism with spasticity (XPDS). Hum Mol Genet, 2013; 22:3259-68. PMC3723311
  62. Kovacs GG, Ferrer I, Grinberg LT, Alafuzoff I, Attems J, Budka H, Cairns NJ, Crary JF, Duyckaerts C, Ghetti B, Halliday GM, Ironside JW, Love S, Mackenzie IR, Munoz DG, Murray ME, Nelson PT, Takahashi H, Trojanowski JQ, Ansorge O, Arzberger T, Baborie A, Beach TG, Bieniek KF, Bigio EH, Bodi I, Dugger BN, Feany M, Gelpi E, Gentleman SM, Giaccone G, Hatanpaa KJ, Heale R, Hof PR, Hofer M, Hortobágyi T, Jellinger K, Jicha GA, Ince P, Kofler J, Kövari E, Kril JJ, Mann DM, Matej R, McKee AC, McLean C, Milenkovic I, Montine TJ, Murayama S, Lee EB, Rahimi J, Rodriguez RD, Rozemüller A, Schneider JA, Schultz C, Seeley W, Seilhean D, Smith C, Tagliavini F, Takao M, Thal DR, Toledo JB, Tolnay M, Troncoso JC, Vinters HV, Weis S, Wharton SB, White CL 3rd, Wisniewski T, Woulfe JM, Yamada M, Dickson DW. Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol. 2016 Jan;131(1):87-102. PMC4879001.
  63. Leverenz JB, Quinn JF, Zabetian C, Zhang J, Montine KS, Montine TJ. Cognitive impairment and dementia in patients with Parkinson disease. Curr Top Med Chem 2009; 9:903-912. PMC2804995
  64. Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson’s disease. Parkinsonism Relat Disord 2011; 17:61-64. PMC3071582 Li X, Rose SE, Montine KS, Keene CD, Montine TJ. Antagonism of neuronal prostaglandin E(2) receptor subtype 1 mitigates amyloid beta neurotoxicity in vitro. J Neuroimmune Pharmacol 2013; 8 87-93. PMC3700810
  65. Liachko NF, McMillan PJ, Guthrie CR, Bird TD, Leverenz JB, Kraemer BC. CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration.Ann Neurol 2013; 74:39-52. PMC3775949
  66. *Liu C, *Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P; The Parkinson Study Group DATATOP Investigators, Zhang J. CSF tau and tau/Aβ(42) predict cognitive decline in Parkinson’s disease. Parkinsonism Relat Disord. 2015 Jan 5. [Epub ahead of print].*co-first authors
  67. Lin X, Cook TJ, Zabetian CP, Leverenz JB, Peskind ER, Hu SC, Cain KC, Pan C, Edgar JS, Goodlett DR, Racette BA, Checkoway H, Montine TJ, Shi M, Zhang J. DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci Rep. 2012; 2:954. PMC3518819.
  68. Lin X, Shi M, Masilamoni JG, Dator R, Movius J, Aro P, Smith Y, Zhang J. Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery. Biochim Biophys Acta 2015; 1854:779-87.PMC4760626
  69. Madhyastha TM, Askren MK, Boord P, Grabowski TJ. Dynamic connectivity at rest predicts attention task performance. Brain Connect 2015; 5:45-59. PMC4313397
  70. Madhyastha T, Askren M, Boord P, Zhang J, Leverenz JB, Grabowski T. Cerebral Perfusion and Cortical Thickness Indicate Cortical Involvement in Mild Parkinson’s disease. Mov Disord. 2015 Dec;30(14):1893-900. PMC4567553.
  71. Madhyastha TM, Askren MK, Zhang J, Leverenz JB, Montine TJ, Grabowski TJ. Group comparison of spatiotemporal dynamics of intrinsic networks in Parkinson’s disease. Brain 2015; 138:2672-86.PMC4643623
  72. Mata IF, Alvarez V, Ribacoba R, Infante J, Sierra M, Gómez-Garre P, Mir P, Waldherr S, Yearout D, Latin American Research Consortium on the Genetics of Parkinson’s Disease, Zabetian CP. Novel Lrrk2-p.S1761R Mutation is not a common cause of Parkinson’s disease in Spain. Mov Disord. 2013; 28:248 PMC3686294
  73. Mata IF, Checkoway H, Hutter CM, Samii A, Roberts JW, Kim HM, Agarwal P, Alvarez V, Ribacoba R, Pastor P, Lorenzo-Betancor O, Infante J, Sierra M, Gomez-Garre P, Mir P, Ritz B, Rhodes SL, Colcher A, Van Deerlin V, Chung KA, Quinn JF, Yearout D, Martinez E, Farin FM, Wan JY, Edwards KL, Zabetian CP Common variation in the LRRK2 gene is a risk factor for Parkinson’s disease. Mov Disord 2012; 27:1822-1825. PMC3536918.
  74. Mata IF, Davis MY, Lopez AN, Dorschner MO, Martinez E, Yearout D, Cholerton BA, Hu SC, Edwards KL, Bird TD, Zabetian CP. The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson’s disease, adds to the complexity of a mutational hotspot. Am J Med Genet B Neuropsychiatr Genet. 2016 Oct;171(7):925-30. PMC5028305
  75. Mata IF, Jang Y, Kim CH, Hanna DS, Dorschner MO, Samii A, Agarwal P, Roberts JW, Klepitskaya O, Shprecher DR, Chung KA, Factor SA, Espay AJ, Revilla FJ, Higgins DS, Litvan I, Leverenz JB, Yearout D, Inca-Martinez M, Martinez E, Thompson TR, Cholerton BA, Hu SC, Edwards KL, Kim KS, Zabetian CP. The RAB39B p.G192R mutation causes X-linked dominant Parkinson’s disease. Mol Neurodegener 2015; 10:50. PMC4581468
  76. Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Goldman JG, Stebbins GT, Bernard B, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Tsuang D, Huston H, Yearout D, Hu SC, Cholerton BA, Montine TJ, Edwards KL, Zabetian CP. GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson’s disease. Mov Disord 2016; 31:95-102. PMC4724255
  77. Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Hurtig HI, Van Deerlin VM, Ritz B, Rausch R, Rhodes SL, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson AL, Espay AJ, Revilla FJ, Devoto J, Hu SC, Cholerton BA, Wan JY, Montine TJ, Edwards KL, Zabetian CP. APOE, MAPT, and SNCA Genes and Cognitive Performance in Parkinson Disease. JAMA Neurol. 2014 Nov 1;71(11):1405-12. PMC4227942.
  78. Mata IF, Shi M, Agarwal P, Chung KA, Edwards KL, Factor SA, Galasko DR, Ginghina C, Griffith A, Higgins DS, Kay DM, Kim H, Leverenz JB, Quinn JF, Roberts JW, Samii A, Snapinn KW, Tsuang DW, Yearout D, Zhang J, Payami H, Zabetian CP. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 2010; 67:1350-1356. PMC3010848
  79. Mata IF, Wilhoite GJ, Yearout D, Bacon JA, Cornejo-Olivas M, Mazzetti P, Marca V, Ortega O, Acosta O, Cosentino C, Torres L, Medina AC, Perez-Pastene C, Diaz-Grez F, Vilarino-Guell C, Venegas P, Miranda M, Trujillo-Godoy O, Layson L, Avello R, Dieguez E, Raggio V, Micheli F, Perandones C, Alvarez V, Segura-Aguilar J, Farrer MJ, Zabetian CP, Ross OA. Lrrk2 p.Q1111H substitution and Parkinson’s disease in Latin America. Parkinsonism Relat Disord 2011; 17:629-631. PMC3167927
  80. Mata IF, Yearout D, Alvarez V, Coto E, de Mena L, Ribacoba R, Lorenzo-Betancor O, Samaranch L, Pastor P, Cervantes S, Infante J, Garcia-Gorostiaga I, Sierra M, Combarros O, Snapinn KW, Edwards KL, Zabetian CP. Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson’s disease. Mov Disord 2011; 26:819-823. PMC3082603
  81. Mattison HA, Nie H, Gao H, Zhou H, Hong J-S, Zhang J. Suppressed pro-inflammatory response of microglia in CX3CR1 knockout mice. J Neuroimmunol 2013; 257:110-5. PMC3702048
  82. Mattsson N, Insel P, Tosun D, Zhang J, Jack CR Jr, Galasko D, Weiner M; Alzheimer’s Disease Neuroimaging Initiative. Effects of baseline CSF α-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer’s disease. PLoS One. 2013; 8:e85443. PMC3877372.
  83. McMillan PJ, Kraemer BC, Robinson L, Leverenz JB, Raskind M, Schellenberg G. Truncation of tau at E391 promotes early pathologic changes in transgenic mice. J Neuropathol Exp Neurol 2011; 70:1006-1019. PMC3237612
  84. McMillan PJ, White SS, Franklin A, Greenup JL, Leverenz JB, Raskind MA, Szot P. Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson’s disease and Alzheimer’s disease. Brain Res 2011; 1373:240-252. PMC3038670
  85. Melief EJ, Cudaback E, Jorstad NL, Sherfield E, Postupna N, Wilson A, Darvas M, Montine KS, Keene CD, Montine TJ. Partial depletion of striatal dopamine enhances penetrance of cognitive deficits in a transgenic mouse model of Alzheimer’s disease. J Neurosci Res 2015; 93:1413-22. PMC4504797
  86. Milatovic D, Montine TJ, Aschner M. Measurement of isoprostanes as markers of oxidative stress. Methods Mol Biol 2011; 758:195-204. PMC3277600
  87. Milatovic D, Montine TJ, Zaja-Milatovic S, Madison JL, Bowman AB, Aschner M. Morphometric analysis in neurodegenerative disorders. Curr Protoc Toxicol 2010; Chapter 12:Unit 12 16. PMC2855147
  88. Millard SP, Lutz F, Li G, Galasko DR, Farlow MR, Quinn JF, Kaye JA, Leverenz JB, Tsuang D, Yu CE, Peskind ER, Bekris LM. Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects. Neurobiol Aging. 2014; 35:357-64. PMC3859300.
  89. Mischley LK, Leverenz JB, Lau RC, Polissar NL, Neradilek MB, Samii A, Standish LJ. A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson’s disease. Mov Disord 2015; 30:1696-701. PMC4609266
  90. Moelter ST, Weintraub D, Mace L, Cary M, Sullo E, Xie SX, Karlawish J. Research consent capacity varies with executive function and memory in Parkinson’s disease. Mov Disord. 2016 Mar;31(3):414-7. PMC5213840.
  91. Mollenhauer B, Zhang J. Biochemical premotor biomarkers for Parkinson’s disease. Mov Disord 2012; 27:644-650. PMC3428741
  92. Montine KS, Montine TJ. Anatomic and clinical pathology of cognitive impairment and dementia. J Alzheimers Dis. 2013; 33 Suppl 1:S181-4. PMC3686298
  93. Montine TJ and Montine KS. Precision medicine: Clarity for the clinical and biological complexity of Alzheimer’s and Parkinson’s diseases. J Exp Med 2015; 212:601-5. PMC4419342
  94. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 2012; 123:1-11. PMC3268003
  95. Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J. CSF Abeta(42) and tau in Parkinson’s disease with cognitive impairment. Mov Disord 2010; 25:2682-2685. PMC2978754
  96. Montine TJ, Sonnen JA, Montine KS, Crane PK, Larson EB. Adult Changes in Thought Study: Dementia is an individually varying convergent syndrome with prevalent clinically silent diseases that may be modified by some commonly used therapeutics. Curr Alzheimer Res 2012; 9:718-723. PMC3409333
  97. Montine TJ. Prevalence estimates for latent neurodegenerative disease. Toxicol Pathol 2011; 39:99-102. PMC3062523
  98. Morgan RG, Gibbs JT, Melief EJ, Postupna NO, Sherfield EE, Wilson A, Keene CD, Montine TJ, Palmiter RD, Darvas M. Relative contributions of severe dopaminergic neuron ablation and dopamine depletion to cognitive impairment. Exp Neurol 2015; 271:205-14. PMC4586402
  99. Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ, Gwinn K, Sutherland M, Martinez M, Heutink P, Williams NM, Hardy J, Gasser T, Brice A, Price TR, Nicolas A, Keller MF, Molony C, Gibbs JR, Chen-Plotkin A, Suh E, Letson C, Fiandaca MS, Mapstone M, Federoff HJ, Noyce AJ, Morris H, Van Deerlin VM, Weintraub D, Zabetian C, Hernandez DG, Lesage S, Mullins M, Conley ED, Northover CA, Frasier M, Marek K, Day-Williams AG, Stone DJ, Ioannidis JP, Singleton AB. Diagnosis of Parkinson’s disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol 2015; 14:1002-9. PMC4575273
  100. Nuytemans K, Inchausti V, Beecham GW, Wang L, Dickson DW, Trojanowski JQ, Lee VM, Mash DC, Frosch MP, Foroud TM, Honig LS, Montine TJ, Dawson TM, Martin ER, Scott WK, Vance JM. Absence of C9ORF72 expanded or intermediate repeats in autopsy-confirmed Parkinson’s disease. Mov Disord. 2014; 29:827-30. PMCID: PMC4022044.
  101. Pan C, Zhou Y, Dator R, Ginghina C, Zhao Y, Movius J, Peskind E, Zabetian CP, Quinn J, Galasko D, Stewart T, Shi M, Zhang J. Targeted discovery and validation of plasma biomarkers of Parkinson’s disease. J Proteome Res. 2014 Nov 7;13(11):4535-45. PMC4224986.
  102. Penzo MA, Robert V, Tucciarone J, De Bundel D, Wang M, Van Aelst L, Darvas M, Parada LF, Palmiter RD, He M, Huang ZJ, Li B. The paraventricular thalamus controls a central amygdala fear circuit. Nature 2015; 519:455-9. PMC4376633
  103. Peterson AL, Murchison C, Zabetian C, Leverenz JB, Watson GS, Montine T, Carney N, Bowman GL, Edwards K, Quinn JF. Memory, mood, and Vitamin D in persons with Parkinson’s disease. J Parkinsons Dis. 2013 ; 3:547-55. PMC3966187
  104. Poorkaj P, Raskind WH, Leverenz JB, Matsushita M, Zabetian CP, Samii A, Kim S, Gazi N, Nutt JG, Wolff J, Yearout D, Greenup JL, Steinbart EJ, Bird TD. A novel X-linked four-repeat tauopathy with Parkinsonism and spasticity. Mov Disord 2010; 25:1409-1417. PMC3123999
  105. Postupna N, Keene CD, Crane PK, Gonzalez-Cuyar LF, Sonnen JA, Hewitt J, Rice S, Howard K, Montine KS, Larson EB, Montine TJ. Cerebral Cortical Aβ42 and PHF-τ in 325 Consecutive Brain Autopsies Stratified by Diagnosis, Location, and APOE. J Neuropathol Exp Neurol. 2015 Feb;74(2):100-9. PMC4294957.
  106. Postupna NO, Keene CD, Latimer C, Sherfield EE, Van Gelder RD, Ojemann JG, Montine TJ, Darvas M. Flow cytometry analysis of synaptosomes from post-mortem human brain reveals changes specific to Lewy body and Alzheimer’s disease. Lab Invest. 2014 Oct;94(10):1161-72. PMC4184945.
  107. Postupna N, Rose SE, Bird TD, Gonzalez-Cuyar LF, Sonnen JA, Larson EB, Keene CD, Montine TJ. Novel antibody capture assay for paraffin-embedded tissue detects wide-ranging amyloid beta and paired helical filament-tau accumulation in cognitively normal older adults. Brain Pathol 2012; 22:472-484. PMC3295908
  108. Qiang JK, Wong YC, Siderowf A, Hurtig HI, Xie SX, Lee VM-Y, Trojanowski JQ, Yearout DB, Leverenz J, Montine TJ, Stern M, Mendick S, Jennings D, Zabetian C, Marek K, Chen-Plotkin AS. Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol 2013; 74:119-27. PMC3773265
  109. Santa-Maria I, Haggiagi A, Liu X, Wasserscheid J, Nelson PT, Dewar K, Clark LN, Crary JF The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol 2012; 124:693-704. PMC3608475
  110. Shang J, Zrazhevskiy P, Postupna N, Keene CD, Montine TJ, Gao X. Multiplexed In-cell Immunoassay for Same-sample Protein Expression Profiling. Sci Rep 2015; 5:13651. PMC4556981
  111. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein D, Zhang J. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011; 69:570-580. PMC3117674
  112. Shi M, Kovac A, Korff A, Cook TJ, Ginghina C, Bullock KM, Yang L, Stewart T, Zheng D, Aro P, Atik A, Kerr KF, Zabetian CP, Peskind ER, Hu SC, Quinn JF, Galasko DR, Montine TJ, Banks WA, Zhang J. CNS tau efflux via exosomes is likely increased in Parkinson’s disease but not in Alzheimer’s disease. Alzheimers Dement. 2016 Nov;12(11):1125-1131. PMC5107127.
  113. Shi M, Furay AR, Sossi V, Aasly JO, Armaly J, Wang Y, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Leverenz JB, Stoessl AJ, Zhang J. DJ-1 and alpha synuclein in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol Aging 2012; 33:836.e5-7. PMC3279603
  114. Shi M, Huber BR, Zhang J. Biomarkers for cognitive impairment in Parkinson disease. Brain Pathol 2010; 20:660-671. PMC2881485
  115. Shi M, Liu C, Cook TJ, Bullock KM, Zhao Y, Ginghina C, Li Y, Aro P, Dator R, He C, Hipp MJ, Zabetian CP, Peskind ER, Hu SC, Quinn JF, Galasko DR, Banks WA, Zhang J. Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease. Acta Neuropathol. 2014 Nov;128(5):639-50. PMC4201967.
  116. Shi M, Movius J, Dator R, Aro P, Zhou Y, Pan C, Lin X, Stewart T, Zabetian CP, Peskind ER, Hu SC, Quinn JF, Galasko DR, Zhang J. Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation. Mol Cell Proteomics 2015; 14:544-55. PMC4349976
  117. Shi M, Sui YT, Peskind ER, Li G, Hwang H, Devic I, Ginghina C, Edgar JS, Pan C, Goodlett DR, Furay AR, Gonzalez-Cuyar LF, Zhang J. Salivary tau species are potential biomarkers of Alzheimer’s disease. J Alzheimers Dis 2011; 27:299-305. PMC3302350
  118. Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Leverenz JB, Zhang J. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson’s disease. Neurosci Lett 2010; 480:78-82. PMC2943649
  119. Shi M, Zhang J. CSF alpha-synuclein, tau, and amyloid beta in Parkinson’s disease. Lancet Neurol 2011; 10:681; author’s reply 681-683. PMC exempt per NIHMS
  120. Silbert LC, Kaye J. Neuroimaging and cognition in Parkinson’s disease dementia. Brain Pathol 2010; 20:646-653. PMC3327506
  121. Smulders K, Dale ML, Carlson-Kuhta P, Nutt JG, Horak FB. Pharmacological treatment in Parkinson’s disease: Effects on gait. Parkinsonism Relat Disord. 2016 Oct;31:3-13. PMC5048566.
  122. Snapinn KW, Larson EB, Kawakami H, Ujike H, Borenstein AR, Izumi Y, Kaji R, Maruyama H, Mata IF, Morino H, Oda M, Tsuang DW, Yearout D, Edwards KL, Zabetian CP. The UCHL1 S18Y polymorphism and Parkinson’s disease in a Japanese population. Parkinsonism Relat Disord 2011; 17:473-475. PMC3119730
  123. Snyder LR, Hoggard JC, Montine TJ, Synovec RE. Development and application of a comprehensive two-dimensional gas chromatography with time-of-flight mass spectrometry method for the analysis of L-beta-methylamino-alanine in human tissue. J Chromatogr A 2010; 1217:4639-4647. PMC2901168
  124. Sonnen JA, Larson EB, Walker RL, Haneuse S, Crane PK, Gray SL, Breitner JC, Montine TJ. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology 2010; 75:1203-1210. PMC3013492
  125. Sonnen JA, Postupna N, Larson EB, Crane PK, Rose SE, Montine KS, Leverenz JB, Montine TJ. Pathologic correlates of dementia in individuals with Lewy body disease. Brain Pathol 2010; 20:654-659. PMC2881486
  126. Sonnen JA, Santa Cruz K, Hemmy LS, Woltjer R, Leverenz JB, Montine KS, Jack CR, Kaye J, Lim K, Larson EB, White L, Montine TJ. Ecology of the aging human brain. Arch Neurol 2011; 68:1049-1056. PMC3218566
  127. Srivatsal S, Cholerton B, Leverenz JB, Wszolek K, Uitti R,5 Dickson D, Weintraub D, Trojanowski J, Van Deerlin V, Quinn J, Chung K, Peterson A, Factor S, Wood- Siverio C, Goldman J, Stebbins G, Bernard B, Ritz B, Rausch R, Espay A, Revilla F, Devoto J, Rosenthal L, Dawson T, Albert M, Mata IF, Hu S, Montine KS, Johnson C, Montine TJ, Edwards K, Zhang J, Zabetian CP. Cognitive Profile of LRRK2-related Parkinson’s Disease. Mov Disord 2015; 30:728-33. PMC4397146
  128. Stewart T, Liu C, Ginghina C, Cain KC, Auinger P, Cholerton B, Shi M, Zhang J; Parkinson Study Group DATATOP Investigators. Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am J Pathol. 2014; 184:966-75. PMC3969999.
  129. Stewart T, Sui YT, Gonzalez-CF, Wong DT W, Akin DM, Tumas V, Aasly J, Ashmore E, Aro P, Ginghina C, Korff A, Zabetian CP, Leverenz JB, Shi M, Zhang J. Cheek cell-derived alpha-synuclein and DJ-1 do not differentiate Parkinson’s disease from control. Neurobiol Aging 2014; 35;418-20.   PMC3844543
  130. Stewart T, Sossi V, Aasly JO, Wszolek ZK, Uitti RJ, Hasegawa K, Yokoyama T, Zabetian CP, Leverenz JB, Stoessl A, Wang Y, Ginghina C, Liu C, Cain KC, Auinger P, Kang U, Jensen P, Shi M, Zhang J. Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity. Acta Neuropathol Commun. 2015 Jan 31;3(1):7.
  131. Swanson CR, Li K, Unger TL, Gallagher MD, Van Deerlin VM, Agarwal P, Leverenz J, Roberts J, Samii A, Gross RG, Hurtig H, Rick J, Weintraub D, Trojanowski JQ, Zabetian C, Chen-Plotkin AS. Lower plasma Apolipoprotein A1 levels are found in Parkinson’s disease and associate with apolipoprotein A1 genotype. Mov Disord 2015; 30:805-12. PMC4362847
  132. Thomas R, Andrews L, Burman J, Lin, A, Pallanck J. PINK1-Parkin pathway activity is regulated by degradation of PINK1 in the mitochondrial matrix. Plos Genetics. 2014 10:31004279. PMC4038460
  133. Toledo JB, Gopal P, Raible K, Irwin DJ, Brettschneider J, Sedor S, Waits K, Boluda S, Grossman M, Van Deerlin VM, Lee EB, Arnold SE, Duda JE, Hurtig H, Lee VM, Adler CH, Beach TG, Trojanowski JQ. Pathological α-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathology. Acta Neuropathol. 2016 Mar;131(3):393-409. PMC4754135.
  134. Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J. CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer’s disease. Acta Neuropathol 2013; 126:683-97. PMC3812407
  135. Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Kukull W, Nelson PT, Jicha GA, Neltner JH, Galasko D, Masliah E, Trojanowski JQ, Schellenberg GD, Yearout D, Huston H, Fritts-Penniman A, Mata IF, Wan JY, Edwards KL, Montine TJ, Zabetian CP. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology 2012; 79:1944-1950. PMC3484986
  136. Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, Buchman AS, Larson EB, Crane PK, Kaye JA, Kramer P, Woltjer R, Trojanowski JQ, Weintraub D, Chen-Plotkin AS, Irwin DJ, Rick J, Schellenberg GD, Watson GS, Kukull W, Nelson PT, Jicha GA, Neltner JH, Galasko D, Masliah E, Quinn JF, Chung KA, Yearout D, Mata IF, Wan JY, Edwards KL, Montine TJ, Zabetian CP. APOE epsilon 4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 2013; 70:223-8. PMC3580799
  137. Wall VZ, Parker JG, Fadok JP, Darvas M, Zweifel L, Palmiter RD. A behavioral genetics approach to understanding D1 receptor involvement in phasic dopamine signaling. Mol Cell Neurosci 2011; 46:21-31. PMC3035386
  138. Wan JY, Edwards KL, Hutter CM, Mata IF, Samii A, Roberts JW, Agarwal P, Checkoway H, Farin FM, Yearout D, Zabetian CP. Association mapping of the PARK10 region for PD susceptibility genes. Parkinsonism Relat Disord 2014; 20:93-98. PMC3946853
  139. Wang J, Hoekstra JG, Zuo C, Cook TJ, Zhang J. Biomarkers of Parkinson’s disease: current status and future perspectives. Drug Discov Today 2013; 18:155-62. PMC3557745
  140. Wang L, Evatt ML, Maldonado LG, Perry WR, Ritchie JC, Beecham GW, Martin ER, Haines JL, Pericak-Vance MA, Vance JM, Scott WK. Vitamin D from different sources is inversely associated with Parkinson disease. Mov Disord 2015; 30:560-6. PMC4390412
  141. Wang L, Maldonado L, Beecham GW, Martin ER, Evatt ML, Ritchie JC, Haines JL, Zabetian CP, Payami H, Pericak-Vance MA, Vance JM, Scott WK. DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient. Neurol Genet. 2016 Apr 12;2(3):e72. PMC4830205.
  142. Wang W, Darvas M, Storey GP, Bamford IJ, Gibbs JT, Palmiter RD, Bamford NS. Acetylcholine encodes long-lasting presynaptic plasticity at glutamatergic synapses in the dorsal striatum after repeated amphetamine exposure. J Neurosci 2013; 33:10405-26. PMC3685836
  143. Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Edwards KL, Snapinn KW, Goldstein DS, Shi M, Zhang J. Complement 3 and factor h in human cerebrospinal fluid in Parkinson’s disease, Alzheimer’s disease, and multiple-system atrophy. Am J Pathol 2011; 178:1509-1516. PMC3078443
  144. Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, Srulijes K, Trojanowski JQ, Lee VM, Siderowf AD, Hurtig H, Litvan I, Schiess MC, Peskind ER, Masuda M, Hasegawa M, Lin X, Pan C, Galasko D, Goldstein DS, Jensen PH, Yang H, Cain KC, Zhang J. Phosphorylated alpha-synuclein in Parkinson’s disease. Sci Transl Med 2012; 4:121ra120. PMC3302662
  145. Watson GS, Cholerton BA, Gross RG, Weintraub D, Zabetian CP, Trojanowski JQ, Montine TJ, Siderowf A, Leverenz JB. Neuropsychologic assessment in collaborative Parkinson’s disease research: A proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson’s Disease Research at the University of Pennsylvania and the University of Washington. Alzheimers Dement 2013; 9:609-14. PMC3612566
  146. Watson GS, Leverenz JB. Profile of cognitive impairment in Parkinson’s disease. Brain Pathol 2010; 20:640-645. PMC3049172
  147. White LR, Edland SD, Hemmy LS, Montine KS, Zarow C, Sonnen JA, Uyehara-Lock JH, Gelber RP, Ross GW, Petrovitch H, Masaki KH, Lim KO, Launer LJ, Montine TJ. Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies. Neurology. 2016 Mar 15;86(11):1000-8. PMC4799714.
  148. Yang Y, Keene CD, Peskind ER, Galasko DR, Hu SC, Cudaback E, Wilson AM, Li G, Yu CE, Montine KS, Zhang J, Baird GS, Hyman BT, Montine TJ. Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease. J Neuropathol Exp Neurol 2015; 74:672-87. PMC4471879
  149. Zhang J, Mattison HA, Liu C, Ginghina C, Auinger P, McDermott MP, Stewart T, Kang UJ, Parkinson Study Group DATATOP Investigators, Cain KC, Shi M. Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathol 2013; 126:671-82. PMC3796193.